This is not the most recent version of the article. View current version (10 AUG 2015)

Intervention Protocol

You have free access to this content

Oral fumaric acid esters for psoriasis

  1. Ausama Atwan1,
  2. Rachel Abbott2,
  3. Mark J Kelly3,
  4. Timothy Pickles3,
  5. Andrea Bauer4,
  6. Chris Taylor5,
  7. Vincent Piguet1,
  8. John R Ingram1,*

Editorial Group: Cochrane Skin Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010497


How to Cite

Atwan A, Abbott R, Kelly MJ, Pickles T, Bauer A, Taylor C, Piguet V, Ingram JR. Oral fumaric acid esters for psoriasis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010497. DOI: 10.1002/14651858.CD010497.

Author Information

  1. 1

    Cardiff University, Department of Dermatology & Wound Healing, Cardiff Institute of Infection & Immunity, Cardiff, UK

  2. 2

    University Hospital of Wales, Welsh Institute of Dermatology, Cardiff, UK

  3. 3

    Cardiff University, South East Wales Trials Unit, Institute of Translation, Innovation, Methodology and Engagement, Cardiff, Wales, UK

  4. 4

    University Hospital Carl Gustav Carus, Technical University, Department of Dermatology, Dresden, Germany

  5. 5

    c/o Cochrane Skin Group, The University of Nottingham, Nottingham, UK

*John R Ingram, Department of Dermatology & Wound Healing, Cardiff Institute of Infection & Immunity, Cardiff University, 3rd Floor, Glamorgan House, Heath Park, Cardiff, CF14 4XN, UK. ingramjr@cardiff.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (10 AUG 2015)

 
Table 1. Glossary

TermDescription

Adaptive immune systemImmune cells that recognise specific infectious agents and secrete inflammatory cytokines in response

AngiogenicPromoting new blood vessel formation

ApoptosisDeath of a cell

Axial skeletonThe group of bones found along the central axis of the human body, such as the spine

Biologic treatmentA type of drug engineered to alter a specific element of the inflammatory cascade

ChemokinesSmall protein molecules secreted by cells that attract other inflammatory cells to the area

CytokinesSmall protein molecules secreted by cells to communicate with neighbouring cells

EosinophilA cell of the immune system that combats parasite infections and is also involved in reactions to some drugs

ImmunosuppressiveReduction in the activity of the immune system

InflammationA protective response to injury mediated by cells of the immune system, characterised in the skin by redness, heat, swelling, and pain or itch

Innate immune systemImmune cells and proteins, such as complement, that fight infectious agents in a non-specific way

LymphocyteA type of white blood cell involved in the adaptive immune system, which can be subdivided into T cells and B cells

Major histocompatibility complexCell surface molecules involved in recognition of pathogens and tolerance to an individual's own proteins

Psoriasis Area and Severity Index (PASI)A measure of psoriasis severity that includes the extent of body surface area involvement and the maximum thickness, redness, and scaliness of the plaques. Scores range from 0 to 72, and a higher score indicates more severe disease

ScalySilvery-white flakes of skin

T (helper) cellA type of white blood cell involved in the adaptive immune system